TNFR2 is notably prevalent in the central nervous system; thus, the use of TNF-alpha inhibitors might hinder the anti-inflammatory and regenerative impacts of the transmembrane TNF-alpha on TNFR2, potentially fostering demyelination and possibly triggering migraines in patients utilizing such inhibitors [42]. Here, TNFRSF1B is linked to migraine disorder.